Search

Your search keyword '"Verfaillie, Sander C.J."' showing total 9 results
Start Over Author "Verfaillie, Sander C.J." Search Limiters Available in Library Collection
9 results on '"Verfaillie, Sander C.J."'

1. Computer-assisted prediction of clinical progression in the earliest stages of AD

Author

Rhodius-Meester, Hanneke F.M., Liedes, Hilkka, Koikkalainen, Juha, Wolfsgruber, Steffen, Coll-Padros, Nina, Kornhuber, Johannes, Peters, Oliver, Jessen, Frank, Kleineidam, Luca, Molinuevo, José Luis, Rami, Lorena, Teunissen, Charlotte E., Barkhof, Frederik, Sikkes, Sietske A.M., Wesselman, Linda M.P., Slot, Rosalinde E.R., Verfaillie, Sander C.J., Scheltens, Philip, Tijms, Betty M., Lötjönen, Jyrki, and van der Flier, Wiesje M.

Published
2018
Full Text
View/download PDF

3. A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum

Author

Coomans, Emma M., primary, Verberk, Inge M.W., additional, Ossenkoppele, Rik, additional, Verfaillie, Sander C.J., additional, Visser, Denise, additional, Gouda, Mariam, additional, Tuncel, Hayel, additional, Wolters, Emma E., additional, Timmers, Tessa, additional, Windhorst, Albert D., additional, Golla, Sandeep S.V., additional, Scheltens, Philip, additional, van, Wiesje M., additional, Flier, der, additional, van Berckel, Bart N.M., additional, and Teunissen, Charlotte E., additional

Published
2022
Full Text
View/download PDF

5. ATN classification and clinical progression in subjective cognitive decline

Author

Ebenau, Jarith L., Timmers, Tessa, Wesselman, Linda M.P., Verberk, Inge M.W., Verfaillie, Sander C.J., Slot, Rosalinde E.R., van Harten, Argonde C., Teunissen, Charlotte E., Barkhof, Frederik, van den Bosch, Karlijn A., van Leeuwenstijn, Mardou, Tomassen, Jori, den Braber, Anouk, Visser, Pieter Jelle, Prins, Niels D., Sikkes, Sietske A.M., Scheltens, Philip, van Berckel, Bart N.M., and van der Flier, Wiesje M.

Subjects
Male, Amyloid beta-Peptides, Alzheimer Disease, Nerve Degeneration, Disease Progression, Humans, Cognitive Dysfunction, Female, tau Proteins, Middle Aged, Article, Biomarkers, Aged
Abstract

Objective To investigate the relationship between the ATN classification system (amyloid, tau, neurodegeneration) and risk of dementia and cognitive decline in individuals with subjective cognitive decline (SCD). Methods We classified 693 participants with SCD (60 ± 9 years, 41% women, Mini-Mental State Examination score 28 ± 2) from the Amsterdam Dementia Cohort and Subjective Cognitive Impairment Cohort (SCIENCe) project according to the ATN model, as determined by amyloid PET or CSF β-amyloid (A), CSF p-tau (T), and MRI-based medial temporal lobe atrophy (N). All underwent extensive neuropsychological assessment. For 342 participants, follow-up was available (3 ± 2 years). As a control population, we included 124 participants without SCD. Results Fifty-six (n = 385) participants had normal Alzheimer disease (AD) biomarkers (A–T–N–), 27% (n = 186) had non-AD pathologic change (A–T–N+, A–T+N–, A–T+N+), 18% (n = 122) fell within the Alzheimer continuum (A+T–N–, A+T–N+, A+T+N–, A+T+N+). ATN profiles were unevenly distributed, with A–T+N+, A+T–N+, and A+T+N+ containing very few participants. Cox regression showed that compared to A–T–N–, participants in A+ profiles had a higher risk of dementia with a dose–response pattern for number of biomarkers affected. Linear mixed models showed participants in A+ profiles showed a steeper decline on tests addressing memory, attention, language, and executive functions. In the control group, there was no association between ATN and cognition. Conclusions Among individuals presenting with SCD at a memory clinic, those with a biomarker profile A–T+N+, A+T–N–, A+T+N–, and A+T+N+ were at increased risk of dementia, and showed steeper cognitive decline compared to A–T–N– individuals. These results suggest a future where biomarker results could be used for individualized risk profiling in cognitively normal individuals presenting at a memory clinic.

Published
2020

6. Correction to: Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease (European Journal of Nuclear Medicine and Molecular Imaging, (2020), 47, 12, (2866-2878), 10.1007/s00259-020-04758-2)

Author

Wolters, Emma E., Ossenkoppele, Rik, Verfaillie, Sander C.J., Coomans, Emma M., Timmers, Tessa, Visser, Denise, Tuncel, Hayel, Golla, Sandeep S.V., Windhorst, Albert D., Boellaard, Ronald, van der Flier, Wiesje M., Teunissen, Charlotte E., Scheltens, Philip, van Berckel, Bart N.M., Radiology and nuclear medicine, Amsterdam Neuroscience - Neurodegeneration, Neurology, Clinical chemistry, Amsterdam Reproduction & Development (AR&D), APH - Personalized Medicine, and APH - Methodology

Abstract

The authors regret to inform readers that the following error was detected in the original article. The values for entorhinal, limbic and neortical SUVr were switched between SCD Aβ + and Aβ- in Table 1 and have now been corrected. Unnecessary symbols in Table 2 have been removed.

Published
2020

7. Correction to:Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease (European Journal of Nuclear Medicine and Molecular Imaging, (2020), 47, 12, (2866-2878), 10.1007/s00259-020-04758-2)

Author

Wolters, Emma E., Ossenkoppele, Rik, Verfaillie, Sander C.J., Coomans, Emma M., Timmers, Tessa, Visser, Denise, Tuncel, Hayel, Golla, Sandeep S.V., Windhorst, Albert D., Boellaard, Ronald, van der Flier, Wiesje M., Teunissen, Charlotte E., Scheltens, Philip, and van Berckel, Bart N.M.

Abstract

The authors regret to inform readers that the following error was detected in the original article. The values for entorhinal, limbic and neortical SUVr were switched between SCD Aβ + and Aβ- in Table 1 and have now been corrected. Unnecessary symbols in Table 2 have been removed.

Published
2020
Full Text
View/download PDF

8. 18F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers

Author

Wolters, Emma E., Papma, Janne M., Verfaillie, Sander C.J., Visser, Denise, Weltings, Emma, Groot, Colin, van der Ende, Emma L., Giannini, Lucia A.A., Tuncel, Hayel, Timmers, Tessa, Boellaard, Ronald, Yaqub, Maqsood, van Assema, Danielle M.E., Kuijper, Dennis A., Segbers, Marcel, Rozemuller, Annemieke J.M., Barkhof, Frederik, Windhorst, Albert D., van der Flier, Wiesje M., Pijnenburg, Yolande A.L., Scheltens, Philip, van Berckel, Bart N.M., van Swieten, John C., Ossenkoppele, Rik, Seelaar, Harro, Wolters, Emma E., Papma, Janne M., Verfaillie, Sander C.J., Visser, Denise, Weltings, Emma, Groot, Colin, van der Ende, Emma L., Giannini, Lucia A.A., Tuncel, Hayel, Timmers, Tessa, Boellaard, Ronald, Yaqub, Maqsood, van Assema, Danielle M.E., Kuijper, Dennis A., Segbers, Marcel, Rozemuller, Annemieke J.M., Barkhof, Frederik, Windhorst, Albert D., van der Flier, Wiesje M., Pijnenburg, Yolande A.L., Scheltens, Philip, van Berckel, Bart N.M., van Swieten, John C., Ossenkoppele, Rik, and Seelaar, Harro

Abstract

OBJECTIVE: To assess the [18F]flortaucipir binding distribution across MAPT mutations in presymptomatic and symptomatic carriers. METHODS: We compared regional [18F]flortaucipir binding potential (BPND) derived from a 130-minute dynamic [18F]flortaucipir PET scan in 9 (pre)symptomatic MAPT mutation carriers (4 with P301L [1 symptomatic], 2 with R406W [1 symptomatic], 1 presymptomatic L315R, 1 presymptomatic S320F, and 1 symptomatic G272V carrier) with 30 cognitively normal controls and 52 patients with Alzheimer disease. RESULTS: [18F]Flortaucipir BPND images showed overall highest binding in the symptomatic carriers. This was most pronounced in the symptomatic R406W carrier in whom tau binding exceeded the normal control range in the anterior cingulate cortex, insula, amygdala, temporal, parietal, and frontal lobe. Elevated medial temporal lobe BPND was observed in a presymptomatic R406W carrier. The single symptomatic carrier and 1 of the 3 presymptomatic P301L carriers showed elevated [18F]flortaucipir BPND in the insula, parietal, and frontal lobe compared to controls. The symptomatic G272V carrier exhibited a widespread elevated cortical BPND, with at neuropathologic examination a combination of 3R pathology and encephalitis. The L315R presymptomatic mutation carrier showed higher frontal BPND compared to controls. The BPND values of the S320F presymptomatic mutation carrier fell within the range of controls. CONCLUSION: Presymptomatic MAPT mutation carriers already showed subtle elevated tau binding, whereas symptomatic MAPT mutation carriers showed a more marked increase in [18F]flortaucipir BPND. Tau deposition was most pronounced in R406W MAPT (pre)symptomatic mutation carriers, which is associated with both 3R and 4R tau accumulation. Thus, [18F]flortaucipir may serve as an early biomarker for MAPT mutation carriers in mutations that cause 3R/4R tauopathies.

Published
2021

9. Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project

Author

Wesselman, Linda M.P., Doorduijn, Astrid S., Leeuw, Francisca A., de, Verfaillie, Sander C.J., Leeuwenstijn-Koopman, Mardou, van, Slot, Rosalinde E.R., Kester, Maartje I., Prins, Niels D., Rest, Ondine, van de, Schueren, Marian A.E., van der, Scheltens, Philip, Sikkes, Sietske A.M., Flier, Wiesje M., van der, Wesselman, Linda M.P., Doorduijn, Astrid S., Leeuw, Francisca A., de, Verfaillie, Sander C.J., Leeuwenstijn-Koopman, Mardou, van, Slot, Rosalinde E.R., Kester, Maartje I., Prins, Niels D., Rest, Ondine, van de, Schueren, Marian A.E., van der, Scheltens, Philip, Sikkes, Sietske A.M., and Flier, Wiesje M., van der

Abstract

As nutrition is one of the modifiable risk factors for cognitive decline, we studied the relationship between dietary quality and clinical characteristics in cognitively normal individuals with subjective cognitive decline (SCD). We included 165 SCD subjects (age: 64 ± 8 years; 45% female) from the SCIENCe project, a prospective memory clinic based cohort study on SCD. The Dutch Healthy Diet Food Frequency Questionnaire (DHD-FFQ) was used to assess adherence to Dutch guidelines on vegetable, fruit, fibers, fish, saturated fat, trans fatty acids, salt and alcohol intake (item score 0-10, higher score indicating better adherence). We measured global cognition (Mini Mental State Examination), cognitive complaints (Cognitive Change Index self-report; CCI) and depressive symptoms (Center for Epidemiologic Studies Depression Scale; CES-D). Using principal component analysis, we identified dietary components and investigated their relation to clinical characteristics using linear regression models adjusted for age, sex and education. We identified three dietary patterns: (i) "low-Fat-low-Salt", (ii) "high-Veggy", and (iii) "low-Alcohol-low-Fish". Individuals with lower adherence on "low-Fat-low-Salt" had more depressive symptoms (β -0.18 (-2.27--0.16)). Higher adherence to "high-Veggy" was associated with higher MMSE scores (β 0.30 (0.21-0.64)). No associations were found with the low-Alcohol-low-Fish component. We showed that in SCD subjects, dietary quality was related to clinically relevant outcomes. These findings could be useful to identify individuals that might benefit most from nutritional prevention strategies to optimize brain health.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results